Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome

Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome

The combination of verapamil retard and enalapril, or verapamil retard and indapamide SR similarly and significantly increased high-density lipoprotein cholesterol and stable NO2 metabolite levels, reducing platelet aggregation in patients with metabolic syndrome (MS). Compared to the combination of...

Full description

Bibliographic Details
Main Authors: N. M. Krasnova, T. P. Kalashnikova, A. I. Vengerovsky, E. M. Idrisova, I. V. Kulagina, T. E. Suslova, O. V. Gruzdeva, S. V. Kremeno, N. M. Zheltonogova, A. A. Shishkina, R. S. Karpov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2008-06-01
Series:Российский кардиологический журнал
Subjects:
metabolic syndrome
arterial hypertension
platelet aggregation
willebrand factor
no2
verapamil
enalapril
indapamide
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1572
Description
Summary:The combination of verapamil retard and enalapril, or verapamil retard and indapamide SR similarly and significantly increased high-density lipoprotein cholesterol and stable NO2 metabolite levels, reducing platelet aggregation in patients with metabolic syndrome (MS). Compared to the combination of verapamil retard and indapamide SR, the combination of verapamil retard and enalapril significantly reduced atherogenicity coefficient, glycated hemoglobin, glucose and soluble fibrin-monomer complex levels, increasing nitrite concentration and activating plasminogen.
ISSN:1560-4071
2618-7620

Similar Items